TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

More documents

Recommendations

Info

Infect 2009;15:125-36. 2B.77 Ratnaraja NV et al. Current challenges in treating MRSA; what are the options? Expert Rev Anti Infect Ther 2008;6:601-18. 2B.78 Gold FK et al. Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. J Antimicrob Chemother 2009;63:849-61. 2B.79 Cosgrove SE et al. Management of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46(suppl. 5):S386-93. 2B.80 Deresinski S. Methicillin resistant Staphylococcus aureus: an evolutionary, epidemiologic and therapeutic odyssey. Clin Infect Dis 2005;40:562-73. 2B.81 Hsu LY et al. Management of healthcare associated methicillin resistant Staphylococcus aureus. Expert Rev Anti Infect Ther 2005;3:893-905. 2B.82 Kluytmans J et al. Meticillin resistant Staphylococcus aureus in the hospital. Br Med J 2009;338:532- 7. 2B.83 Deresinski S. Vancomycin in combination with other antibiotics for the treatment of serious methicillinresistant Staphylococcus aureus infections. Clin Infect Dis 2009;49:1072-9. 2B.84 Dryden M et al. A European survey of antibiotic management of methicillin-resistant Staphylococcus aureus infection: current clinical opinion and practice. Clin Microbiol Infect 2010;16(suppl. 1):3-30. 2B.85 Denis O et al. Epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) among residents of nursing homes in Belgium. J Antimicrob Chemother 2009;64:1299-306. 2B.86 Nguyen HM et al. Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer? J Antimicrob Chemother 2010;65: 24-36. 2B.87 Teng CS et al. The role of antimicrobial therapy for treatment of uncomplicated skin and soft tissue infections from methicillin-resistant Staphylococcus aureus in children. J Microbiol Immunol Infect 2009;42:324-8. 2B.88 Stryjewski ME et al. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008;46(suppl. 5):S368-77. 2B.89 Daum RS. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med 2007;357:380-90. 2B.90 Zetola N et al. Community acquired methicillin resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis 2005;5:275-86. 2B.91 Kowalski TJ et al. Epidemiology, treatment and prevention of community acquired methicillin resistant Staphylococcus aureus infections. Mayo Clin Proc 2005;80:1201-8. 2B.92 Ellis MW et al. Treatment approaches for community acquired methicillin resistant Staphylococcus aureus infections. Curr Opin Infect Dis 2005;18:496-501. 2B.93 Kollef MH et al. Methicillin resistant Staphylococcus aureus: a new community acquired pathogen? Curr Opin Infect Dis 2006;19:161-8. 2B.94 Diederen BM et al. The emergence of infections with community associated methicillin resistant Staphylococcus aureus. J Infect 2006;52:157-68. 2B.95 Denis O et al. Polyclonal emergence and importation of community acquired methicillin resistant Staphylococcus aureus strains harbouring Panton-Valentine leucocidin genes in Belgium. J Antimicrob Chemother 2005;56:1103-6. 2B.96 Fergie J et al. The treatment of community-acquired methicillin-resistant Staphylococcus aureus infections. Pediatr Infect Dis J 2008;27-67-8. 2B.97 Moellering RC. Current treatment options forcommunity acquired methicillin resistant Staphylococcus aureus infection. Clin Infect Dis 2008;46:1032-7. 2B.98 Powell JP et al. Antibiotic options for treating community-acquired MRSA. Expert Rev Anti Infect Ther 2008;6:299-307. 2B.99 Nathwani D et al. Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community. J Antimicrob Chemother 2008;61:976-94. 2B.100 Cenizal MJ et al. Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2007;51:2628-30. 2B.101 Elliott DJ et al. Empiric antimicrobial therapy for pediatric skin and soft-tissue infections in the era of methicillin-resistant Staphylococcus aureus. Pediatrics 2009;123:e959-66. 2B.102 Leclercq R. Epidemiological and resistance issues in multidrug-resistant staphylococci and enterococci. Clin Microbiol Infect 2009;15:224-31. 2B.103 Proctor RA. Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2008;46:584-93. 2B.104 Kale-Pradhan P et al. Treatment and recurrence management of staphylococcal infections: community-acquired MRSA. Expert Rev Anti Infect Ther 2008;6:909-15. 2B.105 DeLeo F et al. Community-associated methicillin-resistant Staphylococcus aureus. Lancet 2010;375: 1557-68. 2B.106 Sievert DM et al. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 2008;46:668-74. 2B.107 Sakoulas G et al. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis 2008;46(suppl. 5):S360-7. 2B.108 Pillai SK et al. Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus. Clin Infect Dis 2009;49:1169-74. 2B.109 Howden BP et al. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection and clinical implications. Clin Microbiol Rev 2010;23:99-139. 2B.110 Nonhoff C et al. Low prevalence of methicillin resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in Belgian hospitals. Clin Microbiol Infect 2005;11:214-20. 2B.111 Jones RN. Key considerations in the treatment of complicated staphylococcal infections. Clin Microbiol Infect 2008;14(suppl. 2):3-9. 2B.112 Chang S et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003;348:1342-7. 2B.113 Weinstein MP et al. Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance. Clin Infect Dis 2009;48: 1596-600. 2B.114 Reinert RR. The antimicrobial resistance profile of Streptococcus pneumoniae. Clin Microbiol Infect
2009;15(suppl. 3):7-11. 2B.115 Jacobs MR. Antimicrobial-resistant Streptococcus pneumoniae: trends and management. Expert Rev Anti Infect Ther 2008;6:619-35. 2B.116 Vergison A et al. Epidemiologic features of invasive pneumococcal disease in Belgian children: passive surveillance is not enough. Pediatrics 2006;118:e801-9. 4A.1 Price VE et al. The prevention and management of infections in children with asplenia or hyposplenia. Infect Dis Clin North Am 2007;21:697-710. 4A.2 Kyaw MH et al. Evaluation of severe infection and survival after splenectomy. Am J Med 2006;119: 276.e1-7. 4A.3 American Academy of Pediatrics Committee on Infectious Diseases. Children with asplenia. Red Book 2009;28:84-6. 4A.4 American Academy of Pediatrics Committee on Infectious Diseases. Haemophilus influenzae infections. Red Book 2009;28:314-21. 4A.5 American Academy of Pediatrics Committee on Infectious Diseases. Meningococcal infections. Red Book 2009;28:455-63. 4A.6 American Academy of Pediatrics Committee on Infectious Diseases. Pneumococcal infections. Red Book 2009;28:524-35. 4A.7 American Academy of Pediatrics Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine, pneumococcal polysaccharide vaccine and antibiotic prophylaxis. Pediatrics 2000;106:362- 6. 4A.8 American Academy of Pediatrics Committee on Infectious Diseases. Policy statement: recommendations for the prevention of Streptococcus pneumoniae infections in infants and children, use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23). Pediatrics 2010;126:186-90. 4A.9 Morgan M et al. Dog bites. Br Med J 2007;334:313-7. 4A.10 Nakamura Y et al. Use of appropriate antimicrobials in wound management. Emerg Med Clin North Am 2007;25:159-76. 4A.11 O‘Donnell AE. Bronchiectasis. Chest 2008;134:815-23. 4A.12 Church D et al. Burn wound infections. Clin Microbiol Rev 2006;19:403-34. 4A.13 Benson A et al. Burns. Br Med J 2006;332:649-52. 4A.14 DeSanti L. Pathophysiology and current management of burn injury. Adv Skin Wound Care 2005; 18:323-32. 4A.15 D‘Avignon LC et al. Prevention and management of infections associated with burns in the combat casualty. J Trauma 2008;64(suppl.):S277-86. 4A.16 Sharma BR. Infection in patients with severe burns: causes and prevention thereof. Infect Dis Clin North Am 2007;21:745-59. 4A.17 Gomez M et al. Improved survival following thermal injury in adult patients treated at a regional burn center. J Burn Care Res 2008;29:130-7. 4A.18 Avni T et al. Prophylactic antibiotics for burns patients: systematic review and meta-analysis. Br Med J 2010;340:c241. 4A.19 Garcia-Tsao G et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007;46:922-38. 4A.20 Soares-Weiser K et al. Antibiotic prophylaxis for cirrhotic patients with gastrointestinal bleeding. Cochrane Database Syst Rev 2002;2:CD002907. 4A.21 Steffen R et al. Cholera: assessing the risk to travellers and identifying methods of protection. Travel Med Infect Dis 2003;1:80-8. 4A.22 Starner TD et al. Pathogenesis of early lung disease in cystic fibrosis: a window of opportunity to eradicate bacteria. Ann Intern Med 2005;143:816-22. 4A.23 Ratjen F et al. Cystic fibrosis. Lancet 2003;361:681-9. 4A.24 Geller DE. Aerosol antibiotics in cystic fibrosis. Respir Care 2009;54:658-70. 4A.25 Gibson RL et al. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168:918-51. 4A.26 Ramsey BW et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340:23-30. 4A.27 Moss RB. Administration of aerosolized antibiotics in cystic fibrosis patients. Chest 2001;120(3 suppl.):107S-13S. 4A.28 Shlim DR. Update in traveler‘s diarrhea. Infect Dis Clin North Am 2005;19:137-49. 4A.29 Diemert DJ. Prevention and self-treatment of traveler‘s diarrhea. Clin Microbiol Rev 2006;19:583- 94. 4A.30 DuPont HL. Therapy for and prevention of traveler‘s diarrhea. Clin Infect Dis 2007;45(suppl. 1):S78- 84. 4A.31 Leggat PA et al. Travellers‘ diarrhoea: health advice for travellers. Travel Med Infect Dis 2004;2:17- 22. 4A.32 Rendi-Wagner P et al. Drug prophylaxis for traveler‘s diarrhea. Clin Infect Dis 2002;34:628-33. 4A.33 Jaffer Y et al. A meta-analysis of hemodialysis catheter locking solutions in the prevention of catheterrelated infection. Am J Kidney Dis 2008;51:233-41. 4A.34 Barraclough KA et al. Prevention of access-related infection in dialysis. Expert Rev Anti Infect Ther 2009;7:1185-200. 4A.35 Labriola L et al. Preventing haemodialysis catheter-related bacteraemia with an antimicrobial lock solution: a meta-analysis of prospective randomized trials. Nephrol Dial Transplant 2008;23:1666-72. 4A.36 Kallen AJ et al. Preventing infections in patients undergoing hemodialysis. Expert Rev Anti Infect Ther 2010;8:643-55. 4A.37 Yahav D et al. Antimicrobial lock solutions for the prevention of infections associated with intravascular catheters in patients undergoing hemodialysis: systematic review and meta-analysis of randomized, controlled trials. Clin Infect Dis 2008;47:83-93. 4A.38 James MT et al. Meta-analysis: antibiotics for prophylaxis against hemodialysis catheter-related infections. Ann Intern Med 2008;148:596-605. 4A.39 Berbari EF et al. Dental procedures as risk factors for prosthetic hip or knee infection: a hospital-based prospective case-control study. Clin Infect Dis 2010;50:8-16. 4A.40 Zimmerli W et al. Antibiotics for prevention of periprosthetic joint infection following dentistry: time to focus on data. Clin Infect Dis 2010;50:17-9.
Page 1 and 2: TABLE 39A LIST OF PUBLICATIONS REFE
Page 3 and 4: 1.89 Laupland KB. Vascular and para
Page 5 and 6: of NICE guidance. Br Med J 2008;337
Page 7 and 8: tions à Clostridium difficile dans
Page 9 and 10: sis of placebo-controlled trials. C
Page 11 and 12: 1.446 Centers for Disease Control a
Page 13 and 14: 1.532 Olaison L et al. Enterococcal
Page 15 and 16: 1.615 Muder RR et al. Isolation of
Page 17 and 18: 2005;352:865-74. 1.699 Brown-Elliot
Page 19 and 20: 2009;123:1108-15. 1.782 Ellis MW. A
Page 21 and 22: 1.873 Korting HC et al. Current top
Page 23 and 24: 1.970 Thomas RJ et al. Current mana
Page 25 and 26: of severe respiratory failure. Clin
Page 27 and 28: 1.1166 Aldape MJ et al. Clostridium
Page 29 and 30: 2A.36 Wormser GP. Early Lyme diseas
Page 31 and 32: test methodology. Eur J Clin Microb
Page 33: 2B.39 Cookson BD et al. Guidelines
Page 37 and 38: 82. 4A.87 de Smet AM et al. Deconta
Page 39 and 40: after acute pyelonephritis: a multi
Page 41 and 42: for intensive care patients with no
Page 43 and 44: among hospitalized patients. Clin I
Page 45 and 46: Ther 2006;4:947-52. 5D.1 Demirovic
Page 47 and 48: 7.38 Meersseman W et al. Invasive a
Page 49 and 50: 7.121 Walsh TJ et al. All catheter
Page 51 and 52: nail onychomycosis. J Eur Acad Derm
Page 53 and 54: 2006. Clin Infect Dis 2006;43:1580-
Page 55 and 56: 9A.5 Andes D. Pharmacokinetics and
Page 57 and 58: factor and other newly approved bio
Page 59 and 60: cument E.DEF 8.1). Report of the Su
Page 61 and 62: Br J Dermatol 2004;151:1096-100. 11
Page 63 and 64: new prediction equation. Ann Intern
Page 65 and 66: 14A.93 Sundar S et al. New treatmen
Page 67 and 68: eview. Obstet Gynecol 2005;105:857-
Page 69 and 70: 2003;1:471-82. 14A.278 Walker MD et
Page 71 and 72: 14B.4 Checkley AM et al. Eosinophil
Page 73 and 74: 18.12 Panel on Antiretroviral Thera
Page 75 and 76: 18.91 Lesho E. Evidence base for us
Page 77 and 78: tients. J Antimicrob Chemother 2009
Page 79 and 80: duct characteristics. Available at:
Page 81 and 82: _Product_Information/human/000338/W
Page 83 and 84: 114:23-33. 21.80 Jabs DA et al. Fom
Page 85 and 86:
North Am 2006;20:155-74. 21.176 Nas
Page 87 and 88:
1995;14:827-32. 21.264 Scott LL. Pe
Page 89 and 90:
21.358 Calabrese LH et al. Viral Ar
Page 91 and 92:
24. 21.452 Jeha LE et al. Long term
Page 93 and 94:
induced functional androgen deficie
Page 95 and 96:
25A.27 Conseil Supérieur de la San
Page 97 and 98:
product characteristics. Available
Page 99 and 100:
mortality after kidney transplantat
Page 101 and 102:
33A.1 Kearney BP et al. The penetra
Page 103 and 104:
Clin Plast Surg Clinics in Plastic
Page 105 and 106:
Mycopathologia Mycopathologia Mycos
show all

TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?